You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEtonogestrel
Accession NumberDB00294  (APRD00766)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEtonogestrel is a molecule used in hormonal contraceptives, most notably the subdermal implant Implanon. [Wikipedia]
Structure
Thumb
Synonyms
3-Ketodesogestrel
3-Oxodesogestrel
Etonogestrelum
Implanon
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Implanonimplant68 mg/1subcutaneousOrganon USA Inc.2011-09-06Not applicableUs
Nexplanonimplant68 mg/1subcutaneousOrganon USA Inc.2006-07-17Not applicableUs
Nexplanonimplant68 mg/1subcutaneousOrganon USA Inc.2013-09-27Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixtures
NameLabellerIngredients
NuvaringOrganon USA Inc.
SaltsNot Available
Categories
UNII304GTH6RNH
CAS number54048-10-1
WeightAverage: 324.4565
Monoisotopic: 324.20893014
Chemical FormulaC22H28O2
InChI KeyInChIKey=GCKFUYQCUCGESZ-BPIQYHPVSA-N
InChI
InChI=1S/C22H28O2/c1-4-21-13-14(3)20-17-9-7-16(23)12-15(17)6-8-18(20)19(21)10-11-22(21,24)5-2/h2,12,17-20,24H,3-4,6-11,13H2,1H3/t17-,18-,19-,20+,21-,22-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S)-15-ethyl-14-ethynyl-14-hydroxy-17-methylidenetetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-5-one
SMILES
[H][C@@]12CC[C@@](O)(C#C)[C@@]1(CC)CC(=C)[C@]1([H])[C@@]3([H])CCC(=O)C=C3CC[C@@]21[H]
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as estrogens and derivatives. These are steroids with a structure containing a 3-hydroxylated estrane.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassEstrane steroids
Direct ParentEstrogens and derivatives
Alternative Parents
Substituents
  • Estrogen-skeleton
  • 17-hydroxysteroid
  • Oxosteroid
  • Hydroxysteroid
  • 3-oxosteroid
  • 3-oxo-delta-4-steroid
  • Delta-4-steroid
  • Ynone
  • Tertiary alcohol
  • Cyclic alcohol
  • Cyclic ketone
  • Ketone
  • Hydrocarbon derivative
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor use as a female contraceptive (depot).
PharmacodynamicsEtonogestrel is used as a female contraceptive. Etonogestrel is a progestin or a synthetic form of the naturally occurring female sex hormone, progesterone. In a woman's normal menstrual cycle, an egg matures and is released from the ovaries (ovulation). The ovary then produces progesterone, preventing the release of further eggs and priming the lining of the womb for a possible pregnancy. If pregnancy occurs, progesterone levels in the body remain high, maintaining the womb lining. If pregnancy does not occur, progesterone levels in the body fall, resulting in a menstrual period. Etonogestrel tricks the body processes into thinking that ovulation has already occurred, by maintaining high levels of the synthetic progesterone. This prevents the release of eggs from the ovaries.
Mechanism of actionEtonogestrel binds to the progesterone and estrogen receptors. Target cells include the female reproductive tract, the mammary gland, the hypothalamus, and the pituitary. Once bound to the receptor, progestins like etonogestrel will slow the frequency of release of gonadotropin releasing hormone (GnRH) from the hypothalamus and blunt the pre-ovulatory LH (luteinizing hormone) surge.
Related Articles
AbsorptionNot Available
Volume of distribution
  • 201 L
Protein bindingNot Available
Metabolism

Hepatic.

Route of eliminationExcretion of ENG and its metabolites, either as free steroid or as conjugates, is mainly in urine and to a lesser extent in feces.
Half life25 hours
ClearanceNot Available
ToxicitySymptoms of overdose include nausea, vomiting, vaginal bleeding, and other menstrual irregularities.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9437
Caco-2 permeable+0.8167
P-glycoprotein substrateSubstrate0.6699
P-glycoprotein inhibitor IInhibitor0.6143
P-glycoprotein inhibitor IINon-inhibitor0.8387
Renal organic cation transporterNon-inhibitor0.7587
CYP450 2C9 substrateNon-substrate0.8195
CYP450 2D6 substrateNon-substrate0.9147
CYP450 3A4 substrateSubstrate0.7187
CYP450 1A2 substrateNon-inhibitor0.8898
CYP450 2C9 inhibitorNon-inhibitor0.8939
CYP450 2D6 inhibitorNon-inhibitor0.9224
CYP450 2C19 inhibitorInhibitor0.8755
CYP450 3A4 inhibitorNon-inhibitor0.7496
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.5624
Ames testNon AMES toxic0.9091
CarcinogenicityNon-carcinogens0.9281
BiodegradationNot ready biodegradable0.9864
Rat acute toxicity2.1164 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8206
hERG inhibition (predictor II)Non-inhibitor0.7741
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Organon usa inc
Packagers
Dosage forms
FormRouteStrength
Implantsubcutaneous68 mg/1
Insert, extended releasevaginal
Ring (slow-release)vaginal
Prices
Unit descriptionCostUnit
Implanon 68 mg implant714.34USD each
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5150718 No1992-09-292009-09-29Us
US5989581 No1998-04-082018-04-08Us
US8722037 No2007-09-282027-09-28Us
US8888745 No2006-08-282026-08-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP3.4Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00737 mg/mLALOGPS
logP3.19ALOGPS
logP3.6ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)17.99ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area37.3 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity96.35 m3·mol-1ChemAxon
Polarizability37.77 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Klaus Nickisch, “METHODS FOR THE PREPARATION OF ETONOGESTREL AND DESOGESTREL.” U.S. Patent US20130123523, issued May 16, 2013.

US20130123523
General ReferencesNot Available
External Links
ATC CodesG03AC08
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelDownload (753 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabThe therapeutic efficacy of Abciximab can be decreased when used in combination with Etonogestrel.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Etonogestrel.
AcenocoumarolThe therapeutic efficacy of Acenocoumarol can be decreased when used in combination with Etonogestrel.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Etonogestrel.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Etonogestrel.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Etonogestrel.
AmiodaroneThe metabolism of Etonogestrel can be decreased when combined with Amiodarone.
AncrodThe therapeutic efficacy of Ancrod can be decreased when used in combination with Etonogestrel.
Antithrombin III humanThe therapeutic efficacy of Antithrombin III human can be decreased when used in combination with Etonogestrel.
ApixabanThe therapeutic efficacy of Apixaban can be decreased when used in combination with Etonogestrel.
AprepitantThe serum concentration of Etonogestrel can be increased when it is combined with Aprepitant.
ArdeparinThe therapeutic efficacy of Ardeparin can be decreased when used in combination with Etonogestrel.
ArgatrobanThe therapeutic efficacy of Argatroban can be decreased when used in combination with Etonogestrel.
AtazanavirThe metabolism of Etonogestrel can be decreased when combined with Atazanavir.
AtomoxetineThe metabolism of Etonogestrel can be decreased when combined with Atomoxetine.
BecaplerminThe therapeutic efficacy of Becaplermin can be decreased when used in combination with Etonogestrel.
BexaroteneThe serum concentration of Etonogestrel can be decreased when it is combined with Bexarotene.
BivalirudinThe therapeutic efficacy of Bivalirudin can be decreased when used in combination with Etonogestrel.
BoceprevirThe metabolism of Etonogestrel can be decreased when combined with Boceprevir.
BortezomibThe metabolism of Etonogestrel can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Etonogestrel can be decreased when it is combined with Bosentan.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Etonogestrel.
C1 Esterase Inhibitor (Human)Etonogestrel may increase the thrombogenic activities of C1 Esterase Inhibitor (Human).
C1 Esterase Inhibitor (Recombinant)Etonogestrel may increase the thrombogenic activities of C1 Esterase Inhibitor (Recombinant).
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Etonogestrel.
CarbamazepineThe metabolism of Etonogestrel can be increased when combined with Carbamazepine.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Etonogestrel.
CeritinibThe serum concentration of Etonogestrel can be increased when it is combined with Ceritinib.
CertoparinThe therapeutic efficacy of Certoparin can be decreased when used in combination with Etonogestrel.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Etonogestrel.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Etonogestrel.
Citric AcidThe therapeutic efficacy of Citric Acid can be decreased when used in combination with Etonogestrel.
ClarithromycinThe metabolism of Etonogestrel can be decreased when combined with Clarithromycin.
ClemastineThe metabolism of Etonogestrel can be decreased when combined with Clemastine.
ClotrimazoleThe metabolism of Etonogestrel can be decreased when combined with Clotrimazole.
CobicistatThe metabolism of Etonogestrel can be decreased when combined with Cobicistat.
ConivaptanThe serum concentration of Etonogestrel can be increased when it is combined with Conivaptan.
CrizotinibThe metabolism of Etonogestrel can be decreased when combined with Crizotinib.
CyclosporineThe metabolism of Etonogestrel can be decreased when combined with Cyclosporine.
Dabigatran etexilateThe therapeutic efficacy of Dabigatran etexilate can be decreased when used in combination with Etonogestrel.
DabrafenibThe serum concentration of Etonogestrel can be decreased when it is combined with Dabrafenib.
DalteparinThe therapeutic efficacy of Dalteparin can be decreased when used in combination with Etonogestrel.
DanaparoidThe therapeutic efficacy of Danaparoid can be decreased when used in combination with Etonogestrel.
DarunavirThe metabolism of Etonogestrel can be decreased when combined with Darunavir.
DasatinibThe serum concentration of Etonogestrel can be increased when it is combined with Dasatinib.
DeferasiroxThe serum concentration of Etonogestrel can be decreased when it is combined with Deferasirox.
DelavirdineThe metabolism of Etonogestrel can be decreased when combined with Delavirdine.
DesirudinThe therapeutic efficacy of Desirudin can be decreased when used in combination with Etonogestrel.
DexamethasoneThe serum concentration of Etonogestrel can be decreased when it is combined with Dexamethasone.
DextranThe therapeutic efficacy of Dextran can be decreased when used in combination with Etonogestrel.
Dextran 40The therapeutic efficacy of Dextran 40 can be decreased when used in combination with Etonogestrel.
Dextran 70The therapeutic efficacy of Dextran 70 can be decreased when used in combination with Etonogestrel.
Dextran 75The therapeutic efficacy of Dextran 75 can be decreased when used in combination with Etonogestrel.
DicoumarolThe therapeutic efficacy of Dicoumarol can be decreased when used in combination with Etonogestrel.
DihydroergotamineThe metabolism of Etonogestrel can be decreased when combined with Dihydroergotamine.
DiltiazemThe metabolism of Etonogestrel can be decreased when combined with Diltiazem.
DoxycyclineThe metabolism of Etonogestrel can be decreased when combined with Doxycycline.
DronedaroneThe metabolism of Etonogestrel can be decreased when combined with Dronedarone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Etonogestrel.
Edetic AcidThe therapeutic efficacy of Edetic Acid can be decreased when used in combination with Etonogestrel.
EdoxabanThe therapeutic efficacy of Edoxaban can be decreased when used in combination with Etonogestrel.
EfavirenzThe serum concentration of Etonogestrel can be decreased when it is combined with Efavirenz.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Etonogestrel.
EnoxaparinThe therapeutic efficacy of Enoxaparin can be decreased when used in combination with Etonogestrel.
EnzalutamideThe serum concentration of Etonogestrel can be decreased when it is combined with Enzalutamide.
ErythromycinThe metabolism of Etonogestrel can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Etonogestrel can be decreased when it is combined with Eslicarbazepine acetate.
Ethyl biscoumacetateThe therapeutic efficacy of Ethyl biscoumacetate can be decreased when used in combination with Etonogestrel.
EtravirineThe serum concentration of Etonogestrel can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Etonogestrel.
FluconazoleThe metabolism of Etonogestrel can be decreased when combined with Fluconazole.
FluvoxamineThe metabolism of Etonogestrel can be decreased when combined with Fluvoxamine.
Fondaparinux sodiumThe therapeutic efficacy of Fondaparinux sodium can be decreased when used in combination with Etonogestrel.
FosamprenavirThe metabolism of Etonogestrel can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Etonogestrel can be increased when it is combined with Fosaprepitant.
FosphenytoinThe metabolism of Etonogestrel can be increased when combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Etonogestrel can be increased when it is combined with Fusidic Acid.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Etonogestrel.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Etonogestrel.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Etonogestrel.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Etonogestrel.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Etonogestrel.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Etonogestrel.
HeparinThe therapeutic efficacy of Heparin can be decreased when used in combination with Etonogestrel.
HirulogThe therapeutic efficacy of Hirulog can be decreased when used in combination with Etonogestrel.
IdelalisibThe serum concentration of Etonogestrel can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Etonogestrel can be decreased when combined with Imatinib.
IndinavirThe metabolism of Etonogestrel can be decreased when combined with Indinavir.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Etonogestrel.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Etonogestrel.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Etonogestrel.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Etonogestrel.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Etonogestrel.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Etonogestrel.
IsavuconazoniumThe metabolism of Etonogestrel can be decreased when combined with Isavuconazonium.
IsradipineThe metabolism of Etonogestrel can be decreased when combined with Isradipine.
ItraconazoleThe metabolism of Etonogestrel can be decreased when combined with Itraconazole.
IvacaftorThe serum concentration of Etonogestrel can be increased when it is combined with Ivacaftor.
KetoconazoleThe metabolism of Etonogestrel can be decreased when combined with Ketoconazole.
LepirudinThe therapeutic efficacy of Lepirudin can be decreased when used in combination with Etonogestrel.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Etonogestrel.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Etonogestrel.
LopinavirThe metabolism of Etonogestrel can be decreased when combined with Lopinavir.
LovastatinThe metabolism of Etonogestrel can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Etonogestrel can be increased when it is combined with Luliconazole.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Etonogestrel.
MifepristoneThe metabolism of Etonogestrel can be decreased when combined with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Etonogestrel.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Etonogestrel.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Etonogestrel.
MitotaneThe serum concentration of Etonogestrel can be decreased when it is combined with Mitotane.
ModafinilThe serum concentration of Etonogestrel can be decreased when it is combined with Modafinil.
NadroparinThe therapeutic efficacy of Nadroparin can be decreased when used in combination with Etonogestrel.
NafcillinThe serum concentration of Etonogestrel can be decreased when it is combined with Nafcillin.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Etonogestrel.
NefazodoneThe metabolism of Etonogestrel can be decreased when combined with Nefazodone.
NelfinavirThe metabolism of Etonogestrel can be decreased when combined with Nelfinavir.
NetupitantThe serum concentration of Etonogestrel can be increased when it is combined with Netupitant.
NevirapineThe metabolism of Etonogestrel can be decreased when combined with Nevirapine.
NilotinibThe metabolism of Etonogestrel can be decreased when combined with Nilotinib.
OlaparibThe metabolism of Etonogestrel can be decreased when combined with Olaparib.
OsimertinibThe serum concentration of Etonogestrel can be increased when it is combined with Osimertinib.
OtamixabanThe therapeutic efficacy of Otamixaban can be decreased when used in combination with Etonogestrel.
PalbociclibThe serum concentration of Etonogestrel can be increased when it is combined with Palbociclib.
PentobarbitalThe metabolism of Etonogestrel can be increased when combined with Pentobarbital.
Pentosan PolysulfateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Etonogestrel.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Etonogestrel.
PhenindioneThe therapeutic efficacy of Phenindione can be decreased when used in combination with Etonogestrel.
PhenobarbitalThe metabolism of Etonogestrel can be increased when combined with Phenobarbital.
PhenprocoumonThe therapeutic efficacy of Phenprocoumon can be decreased when used in combination with Etonogestrel.
PhenytoinThe metabolism of Etonogestrel can be increased when combined with Phenytoin.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Etonogestrel.
PosaconazoleThe metabolism of Etonogestrel can be decreased when combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Etonogestrel.
PrimidoneThe metabolism of Etonogestrel can be increased when combined with Primidone.
Protein CThe therapeutic efficacy of Protein C can be decreased when used in combination with Etonogestrel.
ProtocatechualdehydeThe therapeutic efficacy of Protocatechualdehyde can be decreased when used in combination with Etonogestrel.
RanolazineThe metabolism of Etonogestrel can be decreased when combined with Ranolazine.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Etonogestrel.
ReviparinThe therapeutic efficacy of Reviparin can be decreased when used in combination with Etonogestrel.
RifabutinThe metabolism of Etonogestrel can be increased when combined with Rifabutin.
RifampicinThe metabolism of Etonogestrel can be increased when combined with Rifampicin.
RifapentineThe metabolism of Etonogestrel can be increased when combined with Rifapentine.
RitonavirThe metabolism of Etonogestrel can be decreased when combined with Ritonavir.
RivaroxabanThe therapeutic efficacy of Rivaroxaban can be decreased when used in combination with Etonogestrel.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Etonogestrel.
SaquinavirThe metabolism of Etonogestrel can be decreased when combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Etonogestrel.
SildenafilThe metabolism of Etonogestrel can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Etonogestrel can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Etonogestrel can be increased when it is combined with Simeprevir.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Etonogestrel.
St. John's WortThe serum concentration of Etonogestrel can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Etonogestrel can be increased when it is combined with Stiripentol.
SulfisoxazoleThe metabolism of Etonogestrel can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Etonogestrel.
TelaprevirThe metabolism of Etonogestrel can be decreased when combined with Telaprevir.
TelithromycinThe metabolism of Etonogestrel can be decreased when combined with Telithromycin.
TiclopidineThe metabolism of Etonogestrel can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Etonogestrel can be decreased when it is combined with Tocilizumab.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Etonogestrel.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Etonogestrel.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Etonogestrel.
UlipristalThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Ulipristal.
VenlafaxineThe metabolism of Etonogestrel can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Etonogestrel can be decreased when combined with Verapamil.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Etonogestrel.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Etonogestrel.
VoriconazoleThe metabolism of Etonogestrel can be decreased when combined with Voriconazole.
WarfarinThe therapeutic efficacy of Warfarin can be decreased when used in combination with Etonogestrel.
XimelagatranThe therapeutic efficacy of Ximelagatran can be decreased when used in combination with Etonogestrel.
ZiprasidoneThe metabolism of Etonogestrel can be decreased when combined with Ziprasidone.
Food Interactions
  • Avoid alcohol.
  • Avoid excessive quantities of coffee or tea (Caffeine).
  • Increase dietary intake of magnesium, folate, vitamin B6, B12, and/or consider taking a multivitamin.
  • Take at the same time everyday.
  • Take with food.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Molecular Weight:
66215.45 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Progesterone receptor isoform B (PRB) is involved activation of c-SRC/MAPK signaling on hormone stimulation.Isoform A: inactive in stimulating c-Src/MAPK signaling on hormone stimulation.Isoform 4: Increases mitochondrial ...
Gene Name:
PGR
Uniprot ID:
P06401
Molecular Weight:
98979.96 Da
References
  1. Macpherson AM, Archer DF, Leslie S, Charnock-Jones DS, Makkink WK, Smith SK: The effect of etonogestrel on VEGF, oestrogen and progesterone receptor immunoreactivity and endothelial cell number in human endometrium. Hum Reprod. 1999 Dec;14(12):3080-7. [PubMed:10601100 ]
  2. Charnock-Jones DS, Macpherson AM, Archer DF, Leslie S, Makkink WK, Sharkey AM, Smith SK: The effect of progestins on vascular endothelial growth factor, oestrogen receptor and progesterone receptor immunoreactivity and endothelial cell density in human endometrium. Hum Reprod. 2000 Aug;15 Suppl 3:85-95. [PubMed:11041225 ]
  3. Sitruk-Ware R: Pharmacological profile of progestins. Maturitas. 2004 Apr 15;47(4):277-83. [PubMed:15063480 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 27, 2016 02:26